Tesofensine
Tesofensine (NS2330) is an oral triple monoamine reuptake inhibitor that suppresses appetite and supports weight management research.
Total Price
฿3400
For research & laboratory use only. Not for human consumption.
Half-Life
~9 days
Administration Route
Oral capsule
Appetite Control
Triple monoamine reuptake inhibition suppresses hunger
Energy Expenditure
Modestly increases resting metabolic rate
Once-Daily Oral
Long half-life allows simple once-daily oral dosing
Effect Timeline
Reduced appetite and food cravings
Early fat loss as energy intake falls
Substantial weight reduction in clinical research
Start — Week 2
Reduced appetite and food cravings
Week 4
Early fat loss as energy intake falls
Week 12
Substantial weight reduction in clinical research
Mechanism of Action
Scientific Research
Why Researchers Choose Tesofensine
Tesofensine (NS2330) is one of the few orally active, non-injectable appetite-suppression compounds with Phase 2 clinical data, which makes it a practical research tool wherever a peptide-free, central-nervous-system approach to weight management is needed:
- Appetite-regulation and satiety-signalling studies
- Triple monoamine (noradrenaline, dopamine, serotonin) reuptake pharmacology
- Oral versus injectable weight-management comparisons against GLP-1 agonists
- Resting energy-expenditure and metabolic-rate investigations
- Reward-driven and craving-related eating behaviour research
Storage
Storage: keep capsules cool, dry and away from direct light and moisture; keep tightly sealed and away from heat.
Stacking
Tesofensine is generally used as a standalone oral agent in appetite and metabolic research. In comparative studies it is occasionally evaluated alongside GLP-1 receptor agonists to contrast oral central-acting suppression with injectable incretin pathways.
Dosing at a Glance
Route
Oral capsule
Frequency
Once daily (oral capsule)
Typical research dose
250–500 mcg
Opens the calculator with this peptide preselected. Research reference only.